RecruitingNCT03874559

Exosomes in Rectal Cancer

Exosomal as Correlative Biomarker in Clinical Outcomes in Patients Undergoing Neoadjuvant Chemoradiation Therapy for Rectal Cancer

Sponsor

University of Kansas Medical Center

Enrollment

30 participants

Start Date

Feb 13, 2018

Study Type

OBSERVATIONAL

Conditions

Rectal Cancer

Summary

The primary aims of this study is to characterize exosomal biomarker levels in patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation therapy. Compare rates of exosomal expression before during and after chemoradiation therapy with pathologic response rates at the time of APR or LAR. The researchers will also examine the functionality of these exosomes in malignant colonic organoids and mouse models of colorectal cancer.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating whether tiny particles released by rectal cancer tumors into the bloodstream — called exosomes — can be used to predict how well a patient will respond to pre-surgery chemotherapy and radiation treatment. The goal is to develop a simple blood test that tracks treatment response without needing additional biopsies. **You may be eligible if...** - You are 18 or older - You have been diagnosed with rectal cancer confirmed by biopsy (adenocarcinoma) - You are scheduled to receive chemotherapy and radiation therapy before surgery - You are willing and able to proceed with the planned surgery after treatment **You may NOT be eligible if...** - You have had prior pelvic radiation, brachytherapy, or prior chemotherapy - You have had a prior cancer diagnosis other than non-melanoma skin cancer - You are unable or unwilling to undergo surgery - You have a weakened immune system Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.